Research and development costs of Sinovac Biotech Ltd. 2016-2023

In 2023, Sinovac's research and development costs surpassed 344 million U.S. dollars, representing a drop of almost 100 million U.S. dollars from the year before. As one of China's leading vaccine developers, Sinovac's research expenses skyrocketed since the start of the COVID-19 pandemic. The investment paid off with the successful development of CoronaVac, the company's solution to COVID-19. As one of the two major Chinese-made vaccines, CoronaVac generated significant sales, with Sinovac's gross profit surging by more than 4,000 percent in 2021.

于2023年，中国生物制药有限公司的研究与开发支出高达3.44亿美元，较上一年度下降了近1亿美元。作为中国领先的疫苗研发企业之一，自COVID-19疫情爆发以来，中国生物制药有限公司的研发费用急剧攀升。该投资最终收获了丰硕成果，公司成功研发了CoronaVac疫苗，作为应对COVID-19的解决方案。作为两种主要国产疫苗之一，CoronaVac创造了显著的销售业绩，中国生物制药有限公司在2021年的毛利润同比增长超过4000%。